Xeruborbactam
Based on 6 publication(s) in Google Scholar
Xeruborbactam is a potent, ultra-broad-spectrum boronic acid beta-lactamase inhibitor. Xeruborbactam inhibits key serine and metallo beta-lactamases at a nano molar range.
For research use only. We do not sell to patients.
- CAS No.: 2170834-63-4
- Formula: C10H8BFO4
- Molecular Weight:221.98
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications Citing Use of MedChemExpress (MCE) Xeruborbactam
More- Sci Rep. 2025 Sep 29;15(1):33616. [Abstract]
- Int J Infect Dis. 2026 Feb:163:108279. [Abstract]
- Antimicrob Agents Chemother. 2025 Oct 10:e0085725. [Abstract]
- Antimicrob Agents Chemother. 2025 Jul 2;69(7):e0029725. [Abstract]
- Antimicrob Agents Chemother. 2024 Nov 6;68(11):e0077524. [Abstract]
- Antimicrob Agents Chemother. 2024 Jun 5;68(6):e0157023. [Abstract]
Biological Activity
Beta-lactamase[1]
Xeruborbactam is a potent inhibitor of Class D carbapenemases from A. baumannii[1].
Xeruborbactam is minimally affected by the activity of major MDR efflux pumps from P. aeruginosa, representing a significant improvement over the earlier generation boronate beta-lactamase inhibitor (BLI) vaborbactam[1].
The ultra-broad-spectrum beta-lactamase inhibition profile combined with enhancement of the activity of multiple beta-lactam antibiotics with varying sensitivity to the intrinsic resistance mechanisms of efflux and permeability indicate Xeruborbactam is a useful inhibitor for use with multiple beta-lactam antibiotics[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 2170834-63-4
-
Molecular Weight 221.98
-
Formula C10H8BFO4
-
SMILES
FC1=C(C(O)=O)C2=C(C=C1)[C@@H]3[C@@H](C3)B(O)O2
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (6)
-
Journal Impact Factor
-
Most Recent
-
Sci Rep
Sporadic cefiderocol resistance in Escherichia coli from the United Arab Emirates involves multifactorial mechanisms reversible by novel beta-lactamase inhibitors. [Abstract]2025 Sep 29;15(1):33616. PMID: 41023121 -
Int J Infect Dis
Susceptibilities of cefiderocol, meropenem-xeruborbactam, cefepime-taniborbactam, aztreonam-avibactam, and sulbactam-durlobactam against imipenem-non-susceptible Gram-negative bacilli in Taiwan. [Abstract]2026 Feb:163:108279. PMID: 41349864 -
Antimicrob Agents Chemother
Efficacy of cefiderocol in combination with xeruborbactam versus taniborbactam against cefiderocol-resistant NDM-producing Pseudomonas aeruginosa. [Abstract]2025 Oct 10:e0085725. PMID: 41071171 -
Antimicrob Agents Chemother
The emerging concern of IMP variants being resistant to the only IMP-type metallo-β-lactamase inhibitor, xeruborbactam. [Abstract]2025 Jul 2;69(7):e0029725. PMID: 40488615 -
Antimicrob Agents Chemother
Relative inhibitory activities of newly developed diazabicyclooctanes, boronic acid derivatives, and penicillin-based sulfone β-lactamase inhibitors against broad-spectrum AmpC β-lactamases. [Abstract]2024 Nov 6;68(11):e0077524. PMID: 39365068 -
Antimicrob Agents Chemother
Relative inhibitory activities of the broad-spectrum β-lactamase inhibitor xeruborbactam in comparison with taniborbactam against metallo-β-lactamases produced in Escherichia coli and Pseudomonas aeruginosa. [Abstract]2024 Jun 5;68(6):e0157023. PMID: 38727224
Purity & Documentation
References
[1]. Lomovskaya O, et al, The Impact of Intrinsic Resistance Mechanisms on Potency of QPX7728, a New Ultra-Broad-Spectrum Beta-lactamase Inhibitor of Serine and Metallo Beta-Lactamases in Enterobacteriaceae, Pseudomonas aeruginosa, and Acinetobacter baumannii. Antimicrob Agents Chemother. 2020 Mar 30. pii: AAC.00552-20. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)